Da	te: <u>Dec. 25th, 2023</u>			
	ur Name: Xiaoshen Zha	ang		
			entifies key gene signatures predicting therapeutic effi	cary of
	ti-PD-1/PD-L1 monotherapy			cacy or
	nuscript number (if known)			
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmen . If you are in doubt about whether to list a o so.	
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pert e all relationships with manufacturers of antihypertens the manuscript.	
	item #1 below, report all supertime frame for disclosure is	•	ed in this manuscript without time limit. For all other i	tems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	montation,	
		needed)		
		Time frame: Since the initia	al planning of the work	
	All support for the present	Nama		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None		

Time frame: past 36 months

_X__None

X_None

Grants or contracts from any entity (if not indicated

in item #1 above).
Royalties or licenses

3

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
0	Doto ato alla	V N	
8	Patents planned, issued or pending	XNone	
	,0		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board	V 31	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
-	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	maneral interests		
	ease summarize the above co	onflict of interest in the fol	llowing box:
∟ Ple	ease place an "X" next to the	following statement to in	dicate your agreement:

Date	e: <u>Dec. 25th, 2023</u>		
You	r Name: <u>Guanghui Gao</u>		
Man	nuscript Title: <u>In-de</u> r	oth proteomic analysis ide	ntifies key gene signatures predicting therapeutic efficacy of
<u> </u>	-PD-1/PD-L1 monotherapy i		er
Mar	nuscript number (if known):	TLCR-23-713-CL	
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
		o the author's relationship	os/activities/interests as they relate to the <u>current</u>
man	uscript only.		
to the	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	Il planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

Royalties or licenses

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	XNone	
Plea			lowing box:

Date	e: <u>Dec. 25th, 2023</u>		
Your	Name: Qian Zhang		
Man	uscript Title: <u>In-der</u>	oth proteomic analysis ide	ntifies key gene signatures predicting therapeutic efficacy of
	<u>-PD-1/PD-L1 monotherapy i</u>		er
Man	uscript number (if known):	TLCR-23-713-CL	
relat part to tr relat	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so. Os/activities/interests as they relate to the current
to th med In ite	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in th port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	: 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	

Royalties or licenses

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	XNone	
Plea			lowing box:

Date	e: <u>Dec. 25th, 2023</u>		
	r Name: Songchen Zha		
Mar	nuscript Title: <u>In-de</u> r	oth proteomic analysis ider	ntifies key gene signatures predicting therapeutic efficacy of
	-PD-1/PD-L1 monotherapy i		er
Mar	nuscript number (if known):	TLCR-23-713-CL	
rela part to ti	ted to the content of your nices whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	•	l in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	

Royalties or licenses

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	XNone	
Plea			lowing box:

Date	e: <u>Dec. 25th, 2023</u>		
Your	Name: Xuefei Li		
			ntifies key gene signatures predicting therapeutic efficacy of
	PD-1/PD-L1 monotherapy i		er
Man	uscript number (if known):	TLCR-23-713-CL	
relat parti to tr relat The man The to th med	ted to the content of your maies whose interests may be ansparency and does not notionship/activity/interest, it following questions apply to uscript only. author's relationships/activite epidemiology of hyperterication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above)		

Royalties or licenses

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	XNone	
Plea			lowing box:

Date	e: <u>Dec. 25th, 2023</u>		
You	r Name: Wei Cao		
Mar	nuscript Title: <u>In-der</u>	oth proteomic analysis ide	ntifies key gene signatures predicting therapeutic efficacy of
	<u>-PD-1/PD-L1 monotherapy i</u>		er
Man	nuscript number (if known):	TLCR-23-713-CL	
relat part to tr relat	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	ronowing questions apply thuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
med In it	lication, even if that medica	tion is not mentioned in the port for the work reported	all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	ol planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None.	
		Time frame: past	t 36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		

Royalties or licenses

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	XNone	
Plea			lowing box:

Date	: Dec. 25 th , 2023		
Your	Name: Heng Luo		
			tifies key gene signatures predicting therapeutic efficacy of
	PD-1/PD-L1 monotherapy i		er
Man	uscript number (if known):	TLCR-23-713-CL	
relat parti to tr relat The i man The i to th med	ed to the content of your mes whose interests may be ansparency and does not not ionship/activity/interest, it following questions apply to uscript only. author's relationships/activity e epidemiology of hyperterication, even if that medical	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship rities/interests should be dension, you should declare a tion is not mentioned in the port for the work reported	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	

Royalties or licenses

4	Consulting fees	XNone	
_		V N	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone	
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
0	pending		
	F 5		
9	Participation on a Data	X None	
,	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Possint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
13	Other financial or non- financial interests	X None	
Plea	ise summarize the above co	nflict of interest in the foll	owing box:
	N.		
	None.		
D I -		6. II	

Please place an "X" next to the following statement to indicate your agreement:

Date: Dec. 25	th , 2023
Your Name:	Caicun Zhou
Manuscript Title:	In-depth proteomic analysis identifies key gene signatures predicting therapeutic efficacy of
anti-PD-1/PD-L1 r	nonotherapy in non-small-cell lung cancer
Manuscript numb	per (if known): TI CR-23-713-CI

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This study was funded by Shanghai Key clinical specialty construction project - Respiratory Medicine. (201912-0552)	The funding from the government was for me.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
	meetings and, or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
13	Other financial or non- financial interests	XNone	
DI	ase summarize the above co		lander barr

This study was funded by Shanghai Key clinical specialty construction project - Respiratory Medicine (201912-0552)

Please place an "X" next to the following statement to indicate your agreement: